Improves both insulin sensitivity and insulin secretion supporting better blood sugar regulation
This structural difference is why researchers suggest the synthetic peptide may exert a higher affinity towards the target cells and boast a longer half-life
HHSN267200700014C from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF
Administering Sermorelin before bed ensures peak peptide levels coincide with natural nocturnal pulse timing, enhancing rather than disrupting physiologic patterns
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: a multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial